临床试验/NCT00827489

NCT00827489终止1 期

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTC-867 Administered Orally to Healthy Subjects

Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点目标入组 72 人开始时间: 2009年1月最近更新: 2009年9月2日

适应症

干预措施

试验速览

阶段: 1 期
状态: 终止
发起方
入组人数: 72
主要终点: Safety as measured by the number of adverse events and serious adverse events. Tolerability as measured by occurrence of dose limiting toxicities.

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to assess the safety and tolerability of ascending single oral doses of HTC-867 in healthy young and elderly subjects. This study will also evaluate the way the drug enters and leaves the blood and tissues over time and how the drug acts on and in the body in a fasted and fed state.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double (Participant, Investigator)

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

HTC-867

Experimental

干预措施: HTC-867 (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Other)

结局指标

主要结局

Safety as measured by the number of adverse events and serious adverse events. Tolerability as measured by occurrence of dose limiting toxicities.

时间窗: 5 months

次要结局

Pharmacokinetic and pharmacodynamic parameters.(5 months)

研究者

发起方

Wyeth is now a wholly owned subsidiary of Pfizer

申办方类型

Industry

相似试验

撤回

1 期

Study Evaluating Single Doses of GAP-134Healthy Subjects

NCT00820521Wyeth is now a wholly owned subsidiary of Pfizer

已完成

1 期

Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing PotentialFibroid

NCT00427544Wyeth is now a wholly owned subsidiary of Pfizer

已完成

1 期

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRA-027 Administered to Healthy Japanese FemalesUterine Leiomyomata (Fibroids)

NCT00444704Wyeth is now a wholly owned subsidiary of Pfizer

已完成

1 期

Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257Healthy Subjects

NCT00722501Wyeth is now a wholly owned subsidiary of Pfizer48

已完成

1 期

Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy SubjectsHealthy

NCT00550381Wyeth is now a wholly owned subsidiary of Pfizer72